Anzeige
Mehr »
Login
Dienstag, 18.03.2025 Börsentäglich über 12.000 News von 691 internationalen Medien
Spektakuläre News bei dieser Aktie - ist das ist die Chance des Jahres?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 659157 | ISIN: US2561352038 | Ticker-Symbol: RDDA
Frankfurt
18.03.25
08:00 Uhr
12,400 Euro
+0,800
+6,90 %
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
DR REDDYS LABORATORIES LTD ADR Chart 1 Jahr
5-Tage-Chart
DR REDDYS LABORATORIES LTD ADR 5-Tage-Chart
RealtimeGeldBriefZeit
11,80012,50010:40

Aktuelle News zur DR REDDYS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoDr. Reddy's, Sun Pharma and Zydus issue US recalls, citing failed specs and labeling issues3
MoDr Reddy's shares in focus after recall of mislabelled Levetiracetam injection in US2
MoStocks in news: Dr Reddy's, Shilpa Medicare, Voltas, TCS, Tata Motors2
DR REDDYS Aktie jetzt für 0€ handeln
FrDr. Reddy's Labs Recalls Levetiracetam In Sodium Chloride Injection234NEW DELHI (dpa-AFX) - Dr. Reddy's Laboratories Ltd. is recalling select Levetiracetam in Sodium Chloride Injection in the United States citing mislabeling of infusion bag, according to the U.S....
► Artikel lesen
DoDR REDDYS LABORATORIES LTD - 6-K, Report of foreign issuer1
06.03.DR REDDYS LABORATORIES LTD - 6-K, Report of foreign issuer-
04.03.Senores Pharma jumps on inking pact to acquire 14 ANDAs from Dr. Reddy's Labs3
27.02.Dr Reddy's Lab gets EIR from USFDA for Hyderabad facility2
25.02.DR REDDYS LABORATORIES LTD - 6-K, Report of foreign issuer7
19.02.Dr. Reddy's shares fall 6%, Aurobindo Pharma 10% as Trump signals 25% tariffs on pharma imports3
14.02.DR REDDYS LABORATORIES LTD - 6-K, Report of foreign issuer4
14.02.Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories showcases stability with low beta1
07.02.Dr Reddy's and Shanghai Henlius sign agreement for HLX151
06.02.Dr. Reddy's in licenses biosimilar for J&J's multiple myeloma therapy6
06.02.DR REDDYS LABORATORIES LTD - 6-K, Report of foreign issuer-
06.02.Dr. Reddy's Laboratories Ltd.: Dr. Reddy's enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex & Darzalex Faspro in the U.S., and Europe264Dr. Reddy's gets exclusive rights to commercialize the subcutaneous as well as intravenous formulations of HLX15 in the U.S. and Europe Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr....
► Artikel lesen
06.02.Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.191SHANGHAI, Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary...
► Artikel lesen
06.02.Dr Reddys Laboratories Ltd up for third consecutive session2
30.01.Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Bought by Hanson & Doremus Investment Management3
29.01.DR REDDYS LABORATORIES LTD - 6-K, Report of foreign issuer4
Seite:  Weiter >>
117 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1